What Diamens does

Diamens is an Austrian femtech startup founded in 2024 and headquartered at the TechCenter in Linz, Austria. The company is developing what it describes as the world's first at-home molecular diagnostic test for endometriosis, using patient-collected menstrual blood samples analyzed by PCR in a partner laboratory to detect proprietary molecular markers of the disease. The product is targeted at women experiencing symptoms of suspected endometriosis — a condition the company cites as affecting 1 in 10 women globally and currently associated with an average 7-year diagnostic delay, with definitive diagnosis reliant on invasive laparoscopic surgery. Diamens' core value proposition is non-invasive, accessible, affordable, self-collected testing that can be conducted at home without a clinic visit.

The business model is direct-to-consumer: customers obtain an at-home self-sampling kit, collect menstrual blood independently, mail the sample to a partner laboratory for PCR analysis, and receive results within days. Pricing has not been publicly disclosed; the product is positioned on the company website as "einfach und preiswert" (simple and affordable), and the primary revenue stream is described as one-time per-test payment for the kit plus laboratory analysis. The customer segment is singular — symptomatic women self-selecting into a DTC diagnostic — with marketing and distribution run entirely through the company's website (diamens.org). No enterprise channel, healthcare-system payor relationships, or B2B distribution agreements are in place. The product is currently in clinical validation; commercial launch is contingent on completion of the clinical study and European regulatory certification.

The company is led by five co-founders: CEO Marlene Rezk-Füreder (bioinformatics background), COO Clara Ganhör, CSO Angelika Lackner, CTO Eva Scharnagl, and CMO Univ.-Prof. Dr. Peter Oppelt, who is also Professor of Gynecology and Head of the Endometriosis Center at Kepler Universitätsklinikum Linz. The CMO relationship anchors a core clinical co-development partnership with Kepler University Hospital, providing validation infrastructure and clinical expertise. In March 2026, Diamens closed a six-figure seed financing round led by eQventure with participation from VP Venture Partners, FS Life Science Investment, and VGW Beteiligungs GmbH, supplemented by Austrian government grants (including FFG), with use of funds earmarked for clinical validation and European regulatory certification. The company has received regional recognition as a Spin-off Rising Star and is supported by tech2b and SIT within the Austrian startup ecosystem.

Name

Diamens

Legal name

Diamens FlexCo

Website

https://diamens.org

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Diamens is an Austrian femtech startup developing the first at-home menstrual blood-based molecular diagnostic test for endometriosis, using PCR analysis of patient-collected samples. Founded in 2024 in Linz, it targets symptomatic women to address the current 7-year average diagnostic delay.

Ownership category

akta.pro rank

Product category

Women's Health Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industry

At-Home Lab Testing & Diagnostics-Integrated Virtual Care (HLALAAAE)

Keywords

• Molecular diagnostics
• Endometriosis testing
• Menstrual blood diagnostics
• At-home diagnostic kit
• Women's health diagnostics

Headquarters

HQ city

Linz

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Diagnostic Test Kit and Laboratory Analysis: Revenue generated from sale of at-home test kits and associated laboratory PCR analysis services. Customers purchase a kit, self-collect a sample during menstruation, mail it to a partner laboratory, and receive results within days. Pricing has not been publicly disclosed.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Diamens fundamentally develops and sells a non-invasive at-home diagnostic test for endometriosis. Customers receive a self-sampling kit, collect menstrual blood at home during menstruation, mail the sample to a partner laboratory, and receive PCR-based molecular analysis results within days. The test is positioned as the world's first menstrual blood-based endometriosis diagnostic and is designed to be accessible, affordable, and non-invasive.

Product overview

Diamens offers a single diagnostic product: the world's first at-home endometriosis test using menstrual blood. The product consists of a self-sampling kit for patient-collected menstrual blood samples, which are sent to a partner laboratory and analyzed via PCR to detect molecular markers of endometriosis. The company is currently conducting clinical trials and seeking European regulatory certification.

Differentiator

Problem solved

Functional benefit

Products and services

• Endometriosis Diagnostic Test (Menstrual Blood-Based) A non-invasive at-home molecular diagnostic test for endometriosis that uses patient-collected menstrual blood samples analyzed via PCR in a partner laboratory to detect proprietary molecular markers of endometriosis. The product is targeted at women with suspected endometriosis seeking a non-invasive, accessible alternative to surgical diagnosis, with results delivered digitally within days.

Quantifiable outcome

• Currently takes an average of 7 years to diagnose endometriosis via invasive surgery

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• Kepler Universitäts Klinikum Linz (Endometriosezentrum)coreStrategic or Co-development Partner · 1 January 2024Univ.-Prof. Dr. Peter Oppelt, CMO of Diamens, is Professor of Gynecology and Head of the Endometriosis Center at Kepler Universitätsklinikum Linz, providing clinical expertise, validation infrastructure, and medical guidance for the diagnostic test development.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• myLAB Box: US-based DTC at-home diagnostic testing provider covering sexual health, fertility, and women's health. Emerging player: shares the at-home sample collection and lab-analyzed workflow and the women's health DTC consumer, with broader sexual health and STI test offerings.
• Celmatix: US women's reproductive health company combining genomics and diagnostics for fertility and gynecologic conditions. Emerging player: works on molecular diagnostics in adjacent women's reproductive health indications, with a more genomics-led rather than menstrual blood-led approach.
• Inito: India/US fertility diagnostics company offering at-home hormone and ovulation tracking tests. Emerging player: shares the at-home women's reproductive health testing model with digital results, though focused on cycle and fertility rather than disease diagnostics.

Direct peers

• Hera Biotech: US-based femtech developing a non-invasive molecular diagnostic for endometriosis. Direct peer: pursues a similar non-surgical, molecular biomarker strategy to address the same diagnostic delay problem for endometriosis patients.
• NextGen Jane: US-based women's health company developing a menstrual blood ('smart tampon') diagnostic platform for endometriosis and other gynecological conditions. Direct peer: uses the same novel menstrual blood sample type with molecular analysis, targeting the same endometriosis indication through a similar DTC workflow.
• DotLab (now Endogen): US women's health diagnostics company with a blood-based biomarker test for endometriosis. Direct peer: targets the same endometriosis diagnostic market with a non-invasive molecular approach, competing for the same end-patients and physician adoption pathway.

Broad incumbents

• Modern Fertility (Ro): DTC women's reproductive health hormone and fertility testing company, now part of Ro. Broad incumbent: operates a similar DTC at-home sample-collection + lab-analysis model for women's reproductive health, with a broader portfolio but no endometriosis-specific product.
• LetsGetChecked: Global DTC at-home diagnostics company with women's health, hormone, and sexual health test kits. Broad incumbent: shares the home-kit-plus-mail-to-lab model and overlapping women's health customer base, though endometriosis is not in its current portfolio.
• Everlywell: Large US-based DTC at-home diagnostic testing platform spanning women's health, hormones, and infectious disease. Broad incumbent: shares the DTC home-collected-sample-plus-lab workflow with Diamens and competes for the same self-directed women's health consumer.

Others

• Tasso: US company developing at-home self-collection blood collection devices for diagnostics and clinical research. OTHERS: enabling technology provider whose at-home sample collection capability could complement or compete with menstrual blood self-collection workflows in DTC diagnostics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/diamens

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Diamens